Texas Weight Loss Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A clinic can document that it offers semaglutide without documenting that its particular preparation has the same evidence as a product studied in a clinical trial. That distinction is central to Texas Weight Loss. Its public materials describe a medical weight-management business with in-person evaluations, injectable medications, nutrition support and monthly follow-up. They also mention semaglutide with glycine and sourcing through an unnamed 503b compounding pharmacy—details that deserve more attention than a general reference to GLP-1 research.

This review examines public documentation consulted October 19, 2026, separating advertised services, published prices and clinical evidence. Texas Weight Loss provides useful detail about its initial assessment and several charges, but the consulted materials do not establish an all-inclusive treatment cost or identify the exact product behind every semaglutide offer. The practical question is not simply whether semaglutide has research behind it. It is how closely the documented service and medication can be connected to that research.

At a glance

Clinic footprint: Texas Weight Loss advertises six Texas locations, with clinics in Austin, San Antonio and the Houston area.
Sources: [8] [5]
Initial assessment: The $150 initial visit lists a medical consultation, CMP, TSH, lipid panel, HbA1c and body composition analysis; medication costs extra.
Sources: [11]
Published medication price: Semaglutide is listed at $100–275 for a monthly supply depending on dosage, without establishing an inclusive price for visits and medication.
Sources: [11]
Formulation and sourcing: Spanish-language pages describe semaglutide with glycine and semaglutide sourced from a 503b compounding pharmacy, but do not identify that pharmacy or connect every advertised price to a specific formulation.
Sources: [13] [9]
Ongoing care: Monthly follow-up is advertised at $110, with consultation, an appetite-suppressant prescription if medically indicated and four energy-boosting shots; a prescription listing does not establish that medication is included.
Sources: [11] [5]

Start with the medication’s identity, not the headline ingredient

Texas Weight Loss advertises injectable semaglutide and tirzepatide, alongside oral phentermine and other weight-management options. Its Spanish-language semaglutide material describes subcutaneous administration and a preparation enhanced with glycine. Another Spanish-language page attributes its in-house semaglutide supply to a 503b compounding pharmacy. These are meaningful product clues, but they do not establish a manufacturer, pharmacy name, complete formulation or branded product. Nor do they establish that every semaglutide patient receives the same preparation.

The provider presents the pharmacy sourcing as supporting quality control and affordability. Those are commercial claims, not independent findings from this review. The consulted documentation does not identify the pharmacy’s location or establish whether the $100–275 monthly semaglutide price applies specifically to the glycine-containing preparation. Before interpreting either price or effectiveness claims, a prospective patient would need the exact prescribed product, its ingredients and the dispensing pharmacy’s identity.

FDA approval attaches to a specific product, not to a clinic or the ingredient name in its advertising. Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. That fact alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions.

Sources: [9] [13] [11] [1]

What clinical research can—and cannot—add

Semaglutide has randomized-trial evidence, but the study details matter. STEP 1 enrolled 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes, for 68 weeks. Both groups received lifestyle intervention. Mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo. That dose identifies the study arm, not instructions for a reader. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%; Novo Nordisk funded the trial.

Those results do not measure Texas Weight Loss’s performance, its compounded preparations or its semaglutide-with-glycine offering. The consulted clinic materials do not provide a provider-specific outcome dataset with a defined population, follow-up period and accounting for patients who stopped treatment. Claims about rapid weight loss or muscle protection from glycine therefore remain provider claims in this review. The distinction is developed further in why a trial is not a provider performance report.

Tirzepatide is also advertised, but its presence on a service menu does not identify the exact product a patient would receive. SURMOUNT-1 supplies research about studied subcutaneous tirzepatide in a defined population, not about this clinic’s service or an unspecified preparation. Neither that trial nor STEP 1 establishes an individual’s expected result. Comparing separate trial percentages would also not create a randomized head-to-head comparison between medications or a ranking of clinics.

Sources: [9] [13] [3] [4]

The initial visit is more clearly described than GLP-1 eligibility

The documented entry point is a consultation at one of the clinics, where the team discusses goals, reviews medical history and outlines a personalized plan. The GLP-1 page says comprehensive evaluations determine whether these medications may be appropriate. This is an assessment process, not a guaranteed prescription. The public materials consulted do not establish complete GLP-1 eligibility criteria, a minimum age or a uniform pathway for someone seeking exclusively remote care.

The initial-visit description includes blood testing for liver, kidney and thyroid function, a medical consultation and body composition analysis. The price page is more specific, naming CMP, TSH, a lipid panel and HbA1c. The FAQ also says an EKG is required for people with risk factors such as hypertension, diabetes or high cholesterol, and for those 50 or older. It does not establish whether a separately required EKG is included in the advertised visit price.

Phentermine has its own published criteria: the FAQ states a BMI of at least 30 and no comorbid condition. A separate article discusses possible exclusions involving heart disease, uncontrolled high blood pressure or a history of substance misuse. These are the provider’s phentermine statements, not a complete GLP-1 policy and not individualized medical advice. A useful consultation should clarify which assessment applies to the medication actually under consideration.

Sources: [5] [10] [14] [6] [11]

Published prices describe separate pieces of care

The pricing page gives concrete figures rather than requiring every reader to request a quote. The $150 initial visit includes the named laboratory panel, consultation and body composition analysis. It also lists four energy-boosting shots, a diet menu, meal plan and pantry makeover guide. Prescription eligibility is determined at the visit, and medication is an additional charge. These inclusions make the initial assessment relatively legible without turning it into an all-inclusive GLP-1 package.

The $110 monthly follow-up lists a consultation, an appetite-suppressant prescription if medically indicated and four energy-boosting shots. Separately, semaglutide costs $100–275 for a monthly supply depending on dosage. The documentation does not establish that this medication price includes visits, or connect the range to a named formulation and presentation. It also does not publish a tirzepatide price or a combined treatment total. A monthly supply description should not be silently converted to a four-week billing interval.

Additional prices include energy-boosting shots at $20 each or $60 for four, and “Fat Burner” shots at $25 each or $80 for four. The latter package carries an asterisk referring to a buy-three-get-one-free promotion, without further conditions in that block. Standalone body composition analysis is $25. Insurance billing, payment methods, automatic renewal, cancellation, refunds and missed-appointment charges are not established in the consulted materials; a monthly follow-up recommendation alone does not prove a subscription contract.

Published charges and what they establish
Item	Published charge	Important boundary
Initial weight-loss visit	$150	Named labs and assessment included; medication costs extra
Monthly follow-up visit	$110	Lists a prescription if indicated, not medication supplied
Semaglutide	$100–275 per monthly supply, depending on dosage	No combined visit-and-medication total established
Energy-boosting shots	$20 each or $60 for four	Also listed among visit inclusions
“Fat Burner” shots	$25 each or $80 for four	Four-shot package has a buy-three-get-one-free footnote

Sources: [11]

Follow-up includes more than a prescription, at least on paper

Texas Weight Loss asks patients to attend monthly follow-up appointments to track progress, explain results and adjust the plan as needs develop. Its GLP-1 description says individualized plans may include nutrition guidance, lifestyle recommendations, progress monitoring and medication management. These are documented service commitments, although the word “may” matters: the page does not establish an identical set of services or a fixed amount of counseling time for every patient.

Nutrition support is described more concretely in the FAQ, which says meal plans account for lifestyle and dietary preferences and include a menu plus lists of approved and unapproved foods. The semaglutide page also says the team monitors treatment response and offers personalized help managing side effects. What remains unclear is how patients reach that support between appointments, how quickly a clinician responds and whether an unscheduled clinical consultation carries a separate charge.

NIDDK describes follow-up as a question of response and tolerability, not simply renewed payments, and places medication alongside healthy eating and physical activity. That framework helps distinguish a listed benefit from a usable service. Readers can prepare by asking who reviews symptoms, who changes a prescription and what happens if treatment is not tolerated. Our clinical follow-up guide explores those responsibilities without recommending an individual treatment plan.

Sources: [10] [5] [13] [2]

Home injections are documented; delivery arrangements are not

The FAQ says patients may administer injections at home after training from the medical team. It also explicitly says patients can choose not to receive injections. Together, these statements establish flexibility in administration and participation, but they do not promise that a particular non-injectable alternative will be appropriate. They also do not explain whether medication is collected at a clinic, shipped by a pharmacy or supplied through another arrangement.

The consulted materials do not describe shipping fees, dispatch schedules, arrival estimates, refrigeration procedures or replacement policies. They likewise do not identify who handles a damaged or questionable shipment. These are documentation gaps, not evidence that Texas Weight Loss lacks a delivery process. Because the pharmacy is unnamed in the sourcing passage, a reader cannot use that passage alone to trace responsibility from prescription through dispensing and any delivery.

FDA advises patients not to use an injectable GLP-1 medication that arrives warm or with insufficient refrigeration, and to contact the provider or dispensing pharmacy. FDA also reports measurement and administration errors involving compounded medications, including some associated with hospitalization. Training should therefore connect to clear product-specific instructions and an identifiable contact for questions. A review cannot substitute for that instruction, calculate a dose or determine whether a particular delivery is usable.

Sources: [5] [9] [1]

The broader injection menu needs its own evidence questions

This is not a GLP-1-only business. Texas Weight Loss advertises the possibility of prescribing vitamin B-6 injections, NAD+ injections, weight-loss pills and supplements according to personal needs. Its pricing material also lists in-house intramuscular wellness injections including glutathione, vitamin B12, Lipoden, L-Proline, vitamin B1/B6, Plenish and an amino-acid blend. Their presence on the menu establishes availability claims, not proof that each improves weight loss or adds benefit to semaglutide.

The distinction matters because energy-boosting injections appear in both the initial and follow-up visit inclusions. A bundled service can have a published price without having the same research basis as the prescription medication beside it. The provider’s statements about glycine, rapid weight loss or other supportive injections should not borrow credibility automatically from trials of semaglutide or tirzepatide. Readers should ask what outcome an add-on is intended to address and what evidence supports that specific use.

The provider’s safety messaging also warrants clarification. Its FAQ characterizes B12 and Lipoden as lacking significant side effects, while an injection page acknowledges local reactions and allergic reactions with B12. Neither statement should be treated as an independent safety assessment or a guarantee. NIDDK recommends discussing medicines, supplements, allergies and pregnancy plans with the treating clinician. A complete conversation should include the clinic’s add-ons, not only the medication attracting the most attention.

Sources: [12] [11] [13] [9] [5] [2]

A Texas clinic network, with important access details unresolved

Texas Weight Loss says it has 20 years of experience and six locations across Texas. Its location description names Austin, San Antonio and several Houston-area clinics. The website presents Joseph Sleiman with MD and FAAFP credentials; this review did not independently verify credentials or licenses. The documented model is therefore a regional clinic network offering medical weight management, not a verified nationwide telehealth service or an independently audited clinical program.

An after-hours telemedicine announcement says that particular service is exclusively for Texas residents. It does not establish a complete geographic policy for every offering, nor does it provide exact hours, response times, platform details or fees. The public route into care is an invitation to schedule an appointment or contact the clinic. Spanish-language educational pages are available, but their existence does not confirm that every consultation or support channel operates in Spanish.

Several identity and service details remain unresolved: the operating legal entity, the relationship between the Texas Weight Loss names and the clinic45.com support-email domain, and the pharmacy’s identity. These omissions do not demonstrate misconduct or the absence of a service. They limit what a reader can verify before enrollment. A practical next step is to request written answers connecting the clinic, prescriber, dispensing pharmacy, product and charges; our provider-documentation guide explains what those records can establish.

Sources: [8] [5] [9] [7]

Questions & answers

Is Texas Weight Loss’s semaglutide FDA approved?

The consulted documentation does not establish FDA approval of the exact preparation offered. It describes semaglutide with glycine and sourcing from a 503b compounding pharmacy. Compounded preparations are not FDA approved, although nonapproval alone does not establish clinical inequivalence. Ask for the exact product and pharmacy rather than relying on approval language about the ingredient generally.

Sources: [13] [9] [1]

Does the $150 first visit include semaglutide?

No medication inclusion is established. The pricing page states that medication is an additional charge and prescription eligibility is determined during the visit. The $150 assessment lists consultation, specific laboratory tests, body composition analysis and several nutrition and injection benefits. Semaglutide has its own published price of $100–275 per monthly supply depending on dosage.

Sources: [11]

What does the $110 monthly follow-up cover?

The published list includes a medical consultation, an appetite-suppressant prescription if medically indicated and four energy-boosting shots. It says prescription, not medication included. Monthly appointments are intended to review progress and keep the plan tailored to changing needs. The consulted materials do not establish additional-visit fees or whether every GLP-1 patient uses precisely this follow-up arrangement.

Sources: [11] [5]

Can patients give their injections at home?

The FAQ allows home administration after training by the medical team. That does not explain how medication reaches the patient or establish delivery costs and refrigeration procedures. Confirm the dispensing pharmacy, instructions and contact for problems. FDA advises not using injectable GLP-1 medication that arrives warm or inadequately refrigerated and contacting the provider or pharmacy.

Sources: [5] [1]

Can someone outside Texas enroll through telemedicine?

The after-hours telemedicine announcement expressly limits that service to Texas residents. The consulted documentation does not establish broader out-of-state availability or a comprehensive geographic policy. The clinic network is described in Austin, San Antonio and the Houston area. Prospective patients should confirm both location eligibility and whether their initial consultation must occur in a clinic.

Sources: [8] [5]

Must patients choose injections to use the program?

The FAQ says patients may decline injections. Texas Weight Loss also advertises oral phentermine, pills, supplements and nutrition support. That flexibility is not a promise that any particular alternative will be prescribed or appropriate. Its published phentermine criteria are separate from GLP-1 eligibility, and the clinician’s assessment—not the service menu—determines the available individualized options.

Sources: [5] [9]

Our assessment

Texas Weight Loss documents a recognizable care structure: clinic-based assessment, named laboratory tests, nutrition support, monthly follow-up and injection training. Its published visit charges and semaglutide range are useful, especially compared with an entirely quote-only service. The evidence gap lies in connecting those services to an exact medication and verifiable product-specific claims. The unnamed compounding pharmacy, uncertain relationship between the glycine formulation and published price, absent tirzepatide pricing and incomplete delivery and financial terms prevent a fully traceable comparison. Clinical trials support conclusions about their studied treatments, not this provider’s outcomes. Before paying, request written product identification, pharmacy details, an itemized expected bill and clear follow-up responsibilities. Those answers would make the documented offering meaningfully easier to assess without assuming either clinical equivalence or inferiority.

Visit Texas Weight Loss’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Texas Weight Loss Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the medication’s identity, not the headline ingredient

02What clinical research can—and cannot—add

03The initial visit is more clearly described than GLP-1 eligibility

04Published prices describe separate pieces of care

05Follow-up includes more than a prescription, at least on paper

06Home injections are documented; delivery arrangements are not

07The broader injection menu needs its own evidence questions

08A Texas clinic network, with important access details unresolved